Related Experiment Video
Updated: May 21, 2025

Author Spotlight: Evaluating the Therapeutic Efficacy of Moving Cupping Along Meridians for Acute Exacerbation of COPD
Published on: September 27, 2024
[Bronchiectasis disease].
Judith Smith1, Michael Dreher1
1Klinik für Pneumologie und internistische Intensivmedizin, Uniklinik RWTH Aachen, Aachen, Germany.
Bronchiectasis, a chronic inflammatory lung disease, requires increased awareness and timely diagnosis. New treatments are emerging, highlighting the need for updated management strategies and expert surveillance for better patient outcomes.
Area of Science:
- Pulmonology
- Internal Medicine
- Epidemiology
Background:
- Bronchiectasis is a global inflammatory airway disease with diverse causes and significant patient burden.
- Currently, no specific disease-modifying drugs exist for bronchiectasis, except for cystic fibrosis.
- Increasing prevalence necessitates greater awareness among healthcare professionals.
Purpose of the Study:
- To provide an overview of diagnostic algorithms for bronchiectasis.
- To discuss multimodal treatment strategies based on recent research and guidelines.
- To emphasize the role of general practitioners and specialized centers in managing bronchiectasis.
Main Methods:
- Review of current literature and the German bronchiectasis guideline (May 2024).
- Focus on diagnostic criteria and therapeutic approaches.
- Emphasis on practical management for general care practitioners and specialist centers.
Main Results:
- Highlights the importance of early recognition of cardinal symptoms like productive cough and exacerbations.
- Outlines management steps for exacerbations and the need for specialized patient surveillance.
- Anticipates significant changes in treatment and outcomes with upcoming therapies.
Conclusions:
- Increased awareness and prompt diagnosis are crucial for effective bronchiectasis management.
- Multimodal treatment and expert-led surveillance are essential due to disease complexity.
- Emerging disease-modifying drugs promise improved treatment outcomes for bronchiectasis patients.
Related Concept Videos
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Pulmonary Cycle: Exhalation
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...

